Injectable drugs play a crucial role in healthcare, necessitating meticulous attention to primary packaging selection to ensure sterility, stability, and safety. GlobalData’s Drugs database highlights a significant number of US drug approvals between 2022 and 2024, underscoring the importance of parenteral packaging formats like vials, syringes, and auto-injectors. Noteworthy products such as Eli Lilly’s GLP-1 receptor agonists and Genentech’s Vabysmo emphasize the impact of packaging on drug delivery and patient outcomes.
Pharmaceutical companies embarking on the packaging selection process must consider a comprehensive checklist to ensure optimal outcomes. Datwyler, a prominent provider of elastomeric packaging components, advocates for a systematic approach known as “P.E.R.F.E.C.T.”, encompassing key steps like Particulate monitoring, Extractables and Leachables evaluation, Regulatory compliance, Functional assessment, Engineering capabilities, Container Closure Integrity validation, and Total Quality assurance.
Contamination, often linked to particulate matter, poses a significant risk in pharmaceutical manufacturing. To mitigate this, selecting packaging components manufactured in controlled environments with stringent particulate monitoring systems is crucial. Additionally, assessing extractables and leachables potential is vital to prevent undesirable compounds from migrating into the drug product, ensuring patient safety and regulatory adherence.
The evolving regulatory landscape underscores the need for pharmaceutical companies to partner with packaging providers compliant with stringent standards such as ISO 14644-1. Functional performance of packaging systems, whether vials, syringes, or cartridges, is contingent on component compatibility and engineering capabilities. Factors like break-loose force, glide force, and plunger movement are pivotal in evaluating the performance of different packaging systems.
Container Closure Integrity (CCI) must be maintained throughout a product’s shelf life to prevent contamination and leakage. Aspects like plunger-barrel diameter ratios in syringe and cartridge systems, and stopper-vial compatibility in vials, are critical considerations for ensuring effective CCI. Total Quality, encompassing agreed-upon quality measures and defect classification, is essential for aligning manufacturer and recipient expectations regarding product standards.
In conclusion, selecting primary packaging for injectable drugs involves a multifaceted process that demands meticulous attention to detail and adherence to regulatory standards. By prioritizing considerations such as particulate monitoring, E&L risk assessment, regulatory compliance, functional evaluation, engineering capabilities, CCI validation, and Total Quality assurance, pharmaceutical companies can ensure the integrity and safety of their drug products.
Key Takeaways:
1. Particulate monitoring and E&L risk assessment are crucial in mitigating contamination and ensuring patient safety.
2. Regulatory compliance and Total Quality assurance are essential for meeting industry standards and maintaining product integrity.
3. Functional evaluation and engineering capabilities play a key role in determining the performance of packaging components.
4. Container Closure Integrity validation is vital to prevent contamination and leakage throughout a product’s shelf life.
Tags: pharmaceutical manufacturing, regulatory
Read more on pharmaceutical-technology.com